Skip to main content
. 2018 Jun;18(3):196–200. doi: 10.7861/clinmedicine.18-3-196

Table 2.

Indications for performing 25-Hydroxy vitamin D testing across age ranges

Indicationa All (%) 75+ (%) 60–74.9 (%) 30–59.9 (%) <30 (%)
Appropriate
Potent antiresorptive agenta 176 (1.0) 102 (2.2) 58 (1.3) 16 (0.2) 0
Suspected osteomalaciab 3315 (19.0) 751 (16.4) 876 (20.0) 1373 (20.5) 315 (18.3)
Malabsorptionc 331 (1.9) 119 (2.6) 116 (2.6) 184 (2.7) 55 (3.2)
Epilepsy treatmentd 85 (0.5) 7 (0.2) 23 (0.5) 47 (0.7) 8 (0.5)
Total % 22.4 21.3 24.5 24.2 22.0
Uncertain
Fallse 593 (3.4) 441 (9.6) 107 (2.4) 41 (0.6) 4 (0.2)
Osteoporosisf 645 (3.7) 506 (11.0) 280 (6.4) 242 (3.6) 17 (1.0)
Total % 7.1 20.6 8.8 4.2 1.2
Inappropriate (common examples)
Non-specific symptomsg 4492 (26.9) 859 (18.7) 926 (21.1) 2248 (33.5) 652 (37.9)
Proceduralh 3308 (19.0) 1120 (24.4) 899 (20.5) 1048 (15.6) 241 (14.0)
Neuropsychiatrici 503 (2.9) 254 (5.5) 69 (1.6) 137 (2.0) 43 (2.5)
Total (excluding appropriate and uncertain indications) % 70.4 58.1 66.7 71.6 76.8

aStarting on zoledronate or denosumab. bAbnormal calcium or alkaline phosphatase, pain, ache, cramp, myopathy, weakness, mobility or gait disorder. cDiarrhoea, coeliac disease, Crohn's disease, inflammatory bowel disease, cystic fibrosis or gastric bypass. dEpilepsy, valproate, phenytoin, phenobarbital or carbamazepine. eFall, syncope or collapse. fSuspected osteoporosis, fracture, ‘bone screen’ or perioperative period. gTired, fatigue, malaise, exhaustion, ‘off-legs’, general decline, frailty, dizziness, weight loss, sarcopenia, urinary tract infection, pyrexia. hRoutine, screen, review, recheck, repeat, admission, monitor or requested by someone else. iDementia, delirium, confusion, mood disorder or depression.